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Abstract: Human NAD(P)H:quinone oxidoreductase 1 (NQO1) is a multi-functional protein whose
alteration is associated with cancer, Parkinson’s and Alzheimer´s diseases. NQO1 displays a
remarkable functional chemistry, capable of binding different functional ligands that modulate
its activity, stability and interaction with proteins and nucleic acids. Our understanding of this
functional chemistry is limited by the difficulty of obtaining structural and dynamic information
on many of these states. Herein, we have used hydrogen/deuterium exchange monitored by mass
spectrometry (HDXMS) to investigate the structural dynamics of NQO1 in three ligation states:
without ligands (NQO1apo), with FAD (NQO1holo) and with FAD and the inhibitor dicoumarol
(NQO1dic). We show that NQO1apo has a minimally stable folded core holding the protein dimer,
with FAD and dicoumarol binding sites populating binding non-competent conformations. Binding
of FAD significantly decreases protein dynamics and stabilizes the FAD and dicoumarol binding sites
as well as the monomer:monomer interface. Dicoumarol binding further stabilizes all three functional
sites, a result not previously anticipated by available crystallographic models. Our work provides
an experimental perspective into the communication of stability effects through the NQO1 dimer,
which is valuable for understanding at the molecular level the effects of disease-associated variants,
post-translational modifications and ligand binding cooperativity in NQO1.
Keywords: protein structural dynamics; NQO1; ligand binding; protein stability; allostery; protein
degradation
1. Introduction
Human NAD(P)H:quinone oxidoreductase 1 (NQO1; EC 1.6.5.2) is a multifunctional stress protein
mostly localized in the cellular cytosol [1]. NQO1 expression is upregulated as a response to different
types of cellular stress and through several mechanisms, including the antioxidant response through
Nrf2-mediated and Ah2 signaling pathways [1–4].
NQO1 displays multiple enzymatic and non-enzymatic functions [1–5]. NQO1 catalyzes different
reactions with cytoprotective and metabolic roles, such as the two-electron reduction of quinones
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to form hydroquinones [2,6] (Figure 1), redox cycling of quinones [2], reduction of coenzyme Q10
and vitamin E to their antioxidant form [2], scavenging reactive oxygen species [1–3,7], reduction
of catecholamines and vitamin K [1,2] and maintenance of the NADH/NAD+ redox balance [3,8].
The main features of these biochemical reactions involving NQO1 have been investigated in detail
mainly through enzymological and structural analyses. Structurally, the enzyme forms obligate
functional homodimers, with two active sites located in the monomer:monomer interface (MMI),
and each monomer consists of two different domains: (i) an N-terminal domain spanning residues
1–224 that contains part of the active site and is involved in the tight binding of one FAD molecule per
monomer and protein dimerization; (ii) a C-terminal domain (residues 225–274) that contributes to
stabilizing the protein dimer and to the binding of the NAD(P)H coenzyme and the substrates [1,4,9–14].
The functional cycle of NQO1 generally involves two steps according to a ping-pong mechanism: first, in
the reductive half-reaction, an NAD(P)H molecule binds to the enzyme and rapidly reduces the FAD to
FADH2 (with a second-order rate constant of ~106 M−1·s−1) with the subsequent release of the oxidized
nicotinamide dinucleotide; and second, in a very fast oxidative half-reaction (with a second-order
rate constant >109 M−1·s−1), the substrate binds and is reduced by the FADH2, thus regenerating
the flavin in oxidized form and releasing the reduced product [1,10]. This catalytic cycle is known
to be inhibited by different coumarin-based molecules (the best characterized is the biscoumarin,
dicoumarol) that act as competitive inhibitors by blocking the NAD(P)H access to the active site and
partially occupying the NAD(P)H binding site [1,15]. Importantly, comparison of the crystal structures
of NQO1 with FAD bound (NQO1holo) with that containing also dicoumarol bound (NQO1dic) have
revealed that inhibitor binding causes only minor structural rearrangements in the conformation,
which localize at the surface of the catalytic site [15]. Among non-enzymatic functions, we must
highlight the ability of NQO1 to develop protein: protein and protein: RNA interactions [1,2,16–20].
In particular, protein:protein interactions involving NQO1 are relevant to understand its multiple roles
in physiological and pathological processes. NQO1 interacts with key transcription factors associated
with cancer (e.g., p53, p73α and HIF-1α) [17,18] and proteins involved in HIV infection (e.g., Tat
protein) [19], and these interactions increase the intracellular stability of these protein partners by
preventing their degradation by the proteasome. These protein:protein interactions presumably depend
on the functional state of NQO1: binding of NADH may increase the strength of these interactions,
while dicoumarol binding has the opposite effect [9,17,19]. In addition, NQO1holo binds to the 20S
particle of the proteasome and inhibits its proteolytic activity, while FAD withdrawal (i.e., NQO1apo)
renders NQO1 susceptible to degradation by this mechanism [16].
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reduces other organic and inorganic species, such as superoxide radicals and iron(III) ions.
Alterations in NQO1 stability and function are associated to different extents with a variety
of human diseases, including cancer, neurological disorders (such as Parkinson´s and Alzheimer´s
diseases, multiple sclerosis and schizophrenia) and cardiovascular diseases [1,21]. In these cases,
either the wild-type (WT) NQO1 protein and/or a common polymorphic variant (rs1800566, causing a
Pro187Ser amino acid exchange) have been found to be associated with increased disease predisposition.
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The Pro187Ser variant decreases NQO1 activity due to a large defect in FAD binding (10- to 40-fold
lower affinity than that of WT) and in conformational stability, leading to its rapid intracellular
degradation by the proteasome [1,10,14,16,22–25]. In general, reduced NQO1 activity or protein
levels are commonly observed under these pathological conditions [1,26], although for the particular
case of cancer, overexpression of NQO1 is also associated with cancer progression, which makes
pharmacological inhibition of NQO1 (e.g., by dicoumarol or related compounds) a potential therapeutic
strategy to treat this disease if it selectively targets cancer cells [27–29]. Linked to some of these
pathological conditions, the intracellular stability of NQO1 WT is controlled by the population of
the NQO1apo state, which is efficiently targeted to the ubiquitin-dependent proteasomal degradation
pathway [14,25,30]. Recent works also demonstrated that alterations in the phosphorylation pattern of
NQO1 WT at different sites might be associated with these pathological states, likely through effects on
the FAD binding affinity and consequently on the intracellular stability of NQO1 WT [26,30,31].
NQO1 is an excellent model to decipher the role of protein dynamics in the function and stability
of flavin-dependent enzymes, the role of ligand binding in disease-associated protein stability, and the
molecular mechanisms by which mutations cause loss-of-function genetic diseases [1,5,9,10,14,25,30–34].
FAD binding to NQO1 WT triggers a large conformational change, which can be observed by some
biophysical techniques (circular dichroism, infrared and NMR spectroscopies or small-angle X-ray
scattering), and increases the kinetic stability of the protein dimer, although high-resolution structural
information is only available for the NQO1holo state [9–11,14,22,34,35]. This structural change is
accompanied by significant changes in overall protein flexibility (evidence provided by proteolysis
experiments and structure-based analyses of FAD binding energetics) [10,14,34], presumably linked
to the fast degradation of NQO1apo vs. NQO1holo in the cell [14,25], although no high-resolution
experimental information on these dynamic changes is available [14]. Regarding dicoumarol binding,
the comparison of the X-ray crystallographic structures of NQO1holo and NQO1dic has revealed only
local changes in protein structure at the active site [15], and thus, this did not provide details on the
remarkable stabilizing effect of dicoumarol binding on the overall conformational stability and the
dynamics of the C-terminal domain [14]. A critical role of protein dynamics in the mechanisms causing
alterations in NQO1 function due to the Pro187Ser polymorphism and other rare cancer-associated
mutations, phosphorylation at specific sites as well as the effect of suppressor mutations of the Pro187Ser
phenotype have been put forward from experimental and computational studies [5,9,10,14,30–34,36].
Thus, they also await high-resolution information on the changes in protein dynamics due to these
site-specific changes in different ligation states (NQO1apo, NQO1holo and NQO1dic).
We report herein a detailed experimental analysis on the structural dynamics of human NQO1 in
three functionally relevant ligation states (NQO1apo, NQO1holo and NQO1dic). Our results uncover
the existence of a dynamic network within the NQO1 dimer that readily responds to the binding
of functional ligands and help to explain their effects on NQO1 function and stability in vitro and
in vivo. Our work also provides an experimental benchmark to understand the allosteric effects of
disease-associated variants, post-translational modifications and ligand binding in NQO1.
2. Materials and Methods
2.1. Protein Expression and Purification
Protein expression and purification was carried out as described [30]. E. coli BL21(DE3) cells
were transformed with pET46 Ek/LIC vector containing the cDNA of human WT NQO1 [22] and
grown for 16 h in LBA medium (LB containing 0.1 mg·ml−1 ampicillin at 37 ◦C). This culture was
diluted 40-fold in fresh LBA and grown at 37 ◦C for 3 h. Expression was then triggered by the addition
of IPTG (isopropyl β-D-1-thiogalactopyranoside) at a final concentration of 0.5 mM. Induced cells
were incubated for 6 h at 25 ◦C, harvested by centrifugation, washed with binding buffer (BB, 20 mM
sodium phosphate, 300 mM NaCl and 50 mM imidazole at pH 7.4) and frozen overnight at −80 ◦C.
Then, cells were thawed and resuspended in BB containing 1 mM PMSF (phenylmethylsulfonyl
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fluoride) and lysed by sonication. Crude extracts were clarified by centrifugation (20 min at 20,000× g
and 4 ◦C), and supernatants were loaded into immobilized metal affinity chromatography (IMAC)
columns (GE Healthcare) equilibrated in BB. Columns were washed with BB, and the protein was
eluted with elution buffer (BB containing 500 mM imidazole). The eluate was exchanged to 50 mM
K-HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, potassium salt) pH 7.4 using PD-10
columns (GE Healthcare), centrifuged for 30 min at 20,000× g and 4 ◦C, and the UV–visible spectra of
the supernatants were registered in a HP8453 UV–Visible spectrophotomer (Agilent). This purified
holo-protein containing high levels of FAD bound (70%–80% based on the absorbance ratio at 450 nm
and 280 nm; see also [30,33,36]) was stored at −80 ◦C upon flash freezing in liquid N2. Further
purification of the NQO1 dimer was carried out by size-exclusion chromatography using a HiLoad®
16/600 Superdex® 200 prep grade (GE Healthcare) and using 20 mM K-HEPES 200 mM NaCl at pH
7.4 as the mobile phase. This purified protein was subsequently used to obtain apo-protein upon
treatment with BB containing 2 M urea and 2 M KBr, 1 mM DTT (1,4-dithiothreitol) and 1 mM PMSF
at 4 ◦C, and separation of the apo-protein and the FAD released was carried out by IMAC at 4 ◦C.
Apo-proteins were finally exchanged to 50 mM K-HEPES at pH 7.4 using PD-10 columns at 4 ◦C,
concentrated using VIVASPIN 6 30,000 MWCO PES devices (Sartorius) and stored at −80 ◦C after
flash freezing in liquid N2. The purity and integrity of the holo- and apo-protein was checked by
polyacrylamide gel electrophoresis in the presence of sodium dodecylsulphate (SDS-PAGE; Figure S1).
The holo-protein was also found to display enzyme kinetic parameters (Figure S1) consistent with
those previously reported using the same protein construct and purification procedure [9,22].
Purified proteins were also verified by mass spectrometry. The intact mass was analyzed through
direct infusion on ESI-FT-ICR MS (Figure S2), showing that the protein was expressed intact and
lacking the N-terminal Met. The dimeric state of NQO1apo and NQO1holo was verified by native
ESI-MS (Figure S3).
2.2. Hydrogen/Deuterium Exchange Mass Spectrometry (HDXMS)
Amide hydrogen/deuterium exchange (HDX) of NQO1 was followed for its apo (NQO1apo) and
holo (NQO1holo) forms, and the holo form was also analyzed in the presence of dicoumarol (NQO1dic).
Prior to the exchange, the NQO1holo and NQO1dic at 20 µM concentration were pre-incubated with 10
molar excess of FAD for 5 min. NQO1dic was then further mixed with 10 molar excess of dicoumarol
and incubated for another 5 min. The exchange reaction was initiated by a 10-fold dilution into a
D2O-based 50 mM K-HEPES, pD 7.4, 1 mM TCEP (tris(2-carboxyethyl)phosphine). The exchange was
thus followed at 2 µM protein concentration. Deuterium labelling was quenched by 0.5 M Glycine-HCl,
pH 2.3, which was added at 1:1 ratio. The samples were then frozen in liquid N2. Exchange was
followed for 10 s, 30 s, 2 min, 5 min, 20 min, 1 h and 3 h, where 10 s, 5 min and 3 h samples were done
in replicate. Each sample was quickly thawed and injected into a cooled LC system. Here, the protein
was digested on custom-made nepenthesin-2 (Nep-2) and pepsin columns coupled in tandem (each
having a bed volume of 66 µL), and the resulting peptides were trapped on a VanGuard Pre-column
(ACQUITY UPLC BEH C18, 130Å, 1.7 µm, 2.1 mm × 5 mm, Waters, Milford, MA, USA), where they
were desalted. The solvent used for digestion and desalting (0.4% formic acid (FA) in water) was
pumped by a 1260 Infinity II Quaternary pump (Agilent Technologies, Waldbronn, Germany) at a flow
rate of 200 µL·min−1. After three minutes of digestion and desalting, the peptides were separated on
an analytical column (ACQUITY UPLC BEH C18, 130 Å, 1.7 µm, 1 mm × 100 mm, Waters, Milford,
MA, USA) using linear gradient (5%–45% B in 7 min) followed by a quick step to 99% B lasting 5 min.
Solvent A was 0.1% FA/2% acetonitrile (ACN) in water, B was 0.1% FA/98% ACN in water. The gradient
was delivered by the 1290 Infinity II LC System (Agilent Technologies, Waldbronn, Germany) at a
flow of 40 µL·min−1. Digestion, desalting and separation were done at 0 ◦C and pH 2.3 to minimize
deuterium loss. The LC system was connected directly to an electrospray ionization source of a 15T
FT-ICR mass spectrometer (solarix XR, Bruker Daltonics, Bremen, Germany) operating in broad-band
MS mode. Data were peak-picked and exported using DataAnalysis v. 5.0 (Bruker Daltonics, Bremen,
Biomolecules 2019, 9, 728 5 of 17
Germany) and then processed by the in-house developed program Deutex (unpublished). Peptides
arising from the digestion were identified through separate data-dependent LC-MS/MS analyses (using
the same setup as described above) and database searching by the MASCOT algorithm v. 2.4 (Matrix
Science, London, United Kingdom) against a custom-build database containing sequences of pepsin,
nepenthesin-2 and NQO1. Fully deuterated samples were prepared and used for back-exchange
correction as described previously [37,38]. Differences in deuteration can be considered as significant if
they exceed 0.25 Da (calculated as 3× the average standard deviation).
The optimization of digestion conditions, including numerous proteolytical setups, showed that
the serial combination of nepenthesin-2 with pepsin, operated at 200 µL·min−1, provided the best
results in terms of sequence coverage (98.9%, missing the last three amino acids), number of peptides
(140), average peptide length (8.3) and redundancy (4.1) (Figure S4). At this point, it should be also
noted that the region between 100 and 110 yielded peptides of considerable hydrophobicity for which
the signal intensity/quality was just at the threshold level, and thus conclusions derived from their
analyses must be made with caution. The redundant peptide set was used to calculate deuteration in
the shortest possible segments using the overlapping peptides. This analysis provided more detailed
non-redundant information (high-resolution set). Data in this high-resolution set are mainly described
in the manuscript (Figures 2–7, Figure S6 and Table S1), while those using experimental peptides (low
resolution set) are found in Figures S7–S11 and Table S2. Note that the high-resolution set essentially
leads to the same key conclusions as the low resolution one but, in principle, the former narrows the
region for which HDX kinetics is assessed.
To report data on NQO1 segments from HDXMS, we did not consider the His-tag and used the
native sequence from Met1 to Lys274. Therefore, the numbering used throughout the manuscript
differs from that reported in some crystal structures of NQO1, which did not include Met1 and thus
numbered the residues from Val1 to Lys273 (Val2 to Lys274 in the native sequence).
3. Results and Discussion
3.1. A Stable Folded Core in NQO1apo with Highly Dynamic Functional Sites
The results of HDX kinetics for NQO1apo are shown in Figure 2A. Results are presented as the %
of the maximal (theoretical) deuterium incorporation for each segment (%D). Virtually all peptides
characterized in this work for NQO1 complied with EX2 behavior (the presence of a tiny contribution
from the EX1 regime can be detected in a few NQO1 peptides; see Figure S5). In the EX2 mechanism,
the intrinsic exchange rate constant (kint) is much lower than the rate constant (kcl) for the conversion
between non-exchanging (NE-NH) and exchanging (E-NH) states, according to the Linderstrøm-Lang
model (Scheme 1):
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Assuming a pure EX2 behavior, the rate constant for exchange of individual backbone amides
would be equal to the product of the equilibrium constant between NE-NH and E-NH (Kop = kop/kcl)
and kint [39]. Therefore, for this very simple mechanism (note that the conformational equilibrium
is simply two-state and experimental HDX is rarely pure EX2), the experimental rate constant for
exchange reflects to some extent the local stability (e.g., due to hydrogen bonding and burial in the
structure) of the secondary structure.
Overall, the HDX kinetics was very heterogeneous among different protein segments of NQO1apo
(Figure 2A). Most of the segments showed fast HDX kinetics (typically exchanging more than 20%D in
the seconds-minutes time scales) while only a few peptides showed essentially no exchange after 3 h
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(%D < 20). Thus, in a first approach, we simply discerned between exchanging and non-exchanging
segments considering the %D after 3 h (%D < 20 vs. %D ≥ 20, respectively). The functional implications
of this simple analysis were considered regarding those residues in different segments belonging to
three functional sites: the FAD binding site (FBS), the dicoumarol binding site (DBS) and the monomer:
monomer interface (MMI)(see Figure 2A), as provided by analysis of an X-ray crystallographic structure
(PDB 2F1O [15]). It is worth noting that in this structure, the FBS and DBS are located adjacent to each
other in the NQO1 monomer (actually, FAD is structurally part of the DBS), and both sites are close
to the MMI (Figure 2B). Importantly, most of the residues that belong to the FBS, DBS and MMI are
classified as exchanging in NQO1apo (%D ≥ 20; Figure 2A,B).
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crystallographic structure of NQO1 (in a ternary complex with FAD and dicoumarol bound, PDB 
2F1O; NQO1dic) (Figure 3A). Thus, these sequences likely represent regions that are critical for the 
acquisition and maintenance of a minimally stable dimeric fold in NQO1apo (note that NQO1apo is 
dimeric in solution but more expanded and flexible, and with lower conformational stability, than 
NQO1holo [9,14]). This minimal core involves helices α1, α3 and α4 and sheets β1 and β3–β5 (Figures 
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monomers (i.e. the MMI) (Figures 3B and S8). 
Figure 2. Overall HDX kinetics of NQO1apo. (A) HDX kinetics for segments of NQO1apo. Residues
belonging to the monomer: monomer interface (MMI), FAD binding site (FBS) and dicoumarol binding
site (DBS) are indicated as colored circles. These sites were retrieved from the analysis of the NQO1
structure (PDB 2F1O; [15]) using the PISA server (https://www.ebi.ac.uk/pdbe/pisa/); (B) Structural
representation of HDX after 3 h [%D (3 h)] in NQO1apo. For visual aid, the left panel shows the location
of bound FAD and dicoumarol, the middle panel shows those residues belonging to the MMI, FBS and
DBS, and the right panel displays the %D after 3 h for residues belonging to these functional sites.
Within non-exchanging segments, we found that these contained mostly residues buried in the
crystallographic structure of NQO1 (in a ternary complex with FAD and dicoumarol bound, PDB
2F1O; NQO1dic) (Figure 3A). Thus, these sequences likely represent regions that are critical for the
acquisition and maintenance of a minimally stable dimeric fold in NQO1apo (note that NQO1apo
is dimeric in solution but more expanded and flexible, and with lower conformational stability,
than NQO1holo [9,14]). This minimal core involves helices α1, α3 and α4 and sheets β1 and β3–β5
(Figure 3A and Figure S8). This core may also contribute to the acquisition of a minimally folded
monomeric state that becomes stabilized in the dimeric state by the interactions between helices α3
and α4 across the monomers (i.e., the MMI) (Figure 3B and Figure S8).
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Figure 3. Non-exchanging segments define a minimally stable core in NQO1apo. (A) Plot of the % SASA
(solvent accessible surface area) for individual residues (considering backbone and side-chain) calculated
from the structure of NQO1dic (PDB 2F1O [15]) using GETAREA (http://curie.utmb.edu/getarea.html;
this algorithm does not consider the ligands in the calculation). Secondary structure elements are
depicted according to [11]; residues belonging to non-exchanging segments are displayed as green
circles; (B) Structural representation of non-exchanging segments (using PDB 2F1O [15]). The left panel
shows a surface representation highlighting the burial of the minimally stable core. The middle panel
shows segments belonging to this core plotted onto secondary structure elements. The right panel
shows that this core may contribute to the stable folding of the individual monomers as well as their
assembly into the dimer, with only a few stable contacts with the FAD (in orange ball representation)
and the dicoumarol (in yellow ball representation).
Importantly, the FBS and DBS in NQO1apo are overall exchanging (Figure 2B, Figure 3B and
Figure S8B), with the main exceptions being some marginal contacts in helices α1 and α3 (FBS) and α4
(DBS) (Figure 3B and Figure S8B). Thus, our HDX analyses support that the conformational ensemble
of NQO1apo is essentially populated by states non-competent for FAD or dicoumarol binding due to
the high structural dynamics of their binding sites [9,14,34].
3.2. Complex HDX Kinetics
To provide deeper insight into the structural dynamics of NQO1apo, we carefully analyzed the
HDX kinetics for all protein segments (Figure S6). It should be noted that these HDX kinetics were
very consistent with those obtained directly from peptides experimentally characterized (Figure S7
and S11). For the majority of the cases, HDX kinetics was described very well by a simple function
with two kinetic phases (see Figures S6 and S7 for fittings, and Tables S1 and S2 for the best-fit values):
a burst-phase corresponding to HDX mostly occurring within the experimental dead time (i.e., very few
seconds), and thus characterized by a single parameter: its amplitude Aburst; and a slow phase that
occurred typically in a scale of several seconds to minutes, characterized by two parameters: its
amplitude Aslow and an apparent first-order rate constant (kslow), following this equation:
% D(t) = Aburst +Aslow·(1− exp−kslow·t)
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We chose to use this phenomenological description of HDX kinetics mainly for two reasons. First,
it provided a simple scenario from which, using three characteristic parameters (Aburst, Aslow and
kslow), we could compare the HDX kinetics of different segments of NQO1apo (see Figure 4; note that
this approach also worked very well with the HDX kinetics of NQO1holo and NQO1dic; see Figures S6
and S7 and Tables S1 and S2). Second, although HDX kinetics analyzed using more complex functions
(e.g., the two kinetic phases each containing a characteristic rate constant) may provide in some cases
better fits, this would put the analyses at two intertwined risks: increasing the fitting parameters would
make comparisons between behaviors more difficult, and importantly, in many cases these fittings
show evident signs of overparametrization.
Kinetic analyses of HDX for protein segments considered as exchanging (>20%D after 3 h) revealed
certain interesting behaviors. First, for many protein segments (of different lengths), we observed a
significant contribution to the HDX kinetics from both the burst and slow phases (Figure 4 and Figure
S9, and Tables S1 and S2). As indicated above, the HDX kinetics of NQO1 in all three ligation states is
vastly consistent with EX2 kinetics, and thus, the observed kinetics depends to some extent on the
equilibrium constant between non-exchanging and exchanging states [40]. Therefore, the presence
of two clearly differentiated kinetic phases suggests the existence of complexity (i.e., heterogeneity)
in the conformational ensemble of NQO1apo, and plausibly, the significant population of at least
two conformational substates with different HDX behavior, which may or may not significantly
reequilibrate upon the intrinsic HDX step. Interestingly, although ligand binding affects these two
kinetic phases (NQO1holo and NQO1dic, see Figures S6 and S7 and Tables S1 and S2), both these
phases still contribute to the HDX kinetics in these ligation states, suggesting that a certain degree of
conformational heterogeneity remains upon ligand binding. Second, although in the EX2 scenario the
overall kinetics depends on the intrinsic HDX rate constant, and therefore, on the individual backbone
amides and their vicinity [40], some sort of correlated behavior at larger scales than small protein
segments (e.g., secondary structure elements) is observed (Figure 4B and Figure S9). Consistent with
the above-mentioned proposal of a stable core of NQO1apo with highly dynamic FBS and DBS (simply
made by analysis of %D after 3 h, Figure 3), these kinetic analyses suggest that secondary structure
elements outside the stable core typically exchanged quite fast (i.e., with large burst phases and with
kslow often in the range of 10−1 to 10−2 s−1; Figure 4B and Figure S9).
3.3. FAD and Dicoumarol Binding Cause Large-Scale Changes in Protein Structural Dynamics
FAD binding to NQO1apo is known to cause significant overall changes in protein structure
and dynamics: it increases the content in the ordered secondary structure, reduces the protein
hydrodynamic volume, and substantially enhances protein stability and resistance towards proteolytic
attack [9,14,22,34,35]. In addition, structural and biophysical analyses have shown that NQO1 must
contain bound FAD in order to bind dicoumarol with high affinity [9,14]. We first compared the %D
incorporated to NQO1holo and NQO1apo after 3 h of reaction (Figure 5A,B), observing some interesting
changes upon FAD binding. Particularly large differences were observed in loop L1 (involved in the
MMI and the FBS), loop L4 (involved in the MMI, the FBS and the DBS) and helix α5 (involved in the
FBS). The stabilization observed for the MMI thus explains the increased thermostability of the NQO1
dimer upon FAD binding. The much lower structural dynamics of the FBS upon FAD binding is also
consistent with an induced-fit mechanism, in which binding competent states (with high structural
stability) are marginally populated in the absence of FAD, according to a recent proposal based on
binding structure-thermodynamic relationships [34]. Interestingly, these results also imply that FAD is
not only required for dicoumarol binding as a part of the DBS, but also that FAD binding modifies
the dynamics of protein structural elements involved in the binding of the inhibitor (Figure 5C). It is
worth noting that FAD binding also significantly slows down (3- to 5-fold) HDX of other regions such
as sheet β6, helix α7 and loop L3 (Figure 6 and Figure S6, and Table S1), some of them not directly
involved in the MMI, FBS or DBS.
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belonging to the sites that displayed at least a decrease of 10%D after 3 h in NQO1holo (middle panel)
or NQO1dic (right panel) vs. NQO1apo.
Dicoumarol binding to NQO1holo is also known to increase the protein ordered secondary structure,
thermal stability and resistance of the N-terminal domain towards proteolysis [9,14]. According to
this evidence, we observed that dicoumarol binding to NQO1holo decreased the %D after 3 h to an
even larger extent than FAD binding, and these effects seemed to propagate to more distant regions in
the protein structure, extensively affecting regions involved in the MMI, the FBS and DBS (Figure 5).
The regions affected by dicoumarol binding were actually the very same set of structural regions
affected by FAD binding with the exception of helix α5 (Figure 5). In contrast to FAD, dicoumarol
binding also caused a dramatic reduction in %D in sheet β4 and loop L5, which contain residues
belonging to the MMI and the DBS (Figure 5). In addition, dicoumarol binding slowed down the HDX
kinetics of helix α7 and loops L4 and L5 (Figure 6 and Figures S6 and S7, and Tables S1 and S2) by
several orders of magnitude.
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Right panels show fittings of HDX kinetics for selected individual segments using a single exponential
function with a burst-phase for QO1apo (grey), NQO1ho o (black) and NQO1dic (red). These data
were used to calculate ∆%D v, as an average of the time points with maximal differences between
a given NQO1 form (NQO1holo, black; NQO1dic, red) nd NQO1apo, as a single metri to quantify
changes HDX kinetics (left panels).
Clearly, the HDX kinetics of NQO1 in all thre ligation stat s ( o, NQO1h lo and NQO1dic)
wer complex overal Figures S6 and S7). Therefore, i was no straightforward to
provide a singl metric from the global kinetic analysis reported so far in this work, even when
a simple kinetic model was used. To quantify the effects of ligand binding (a d po entially of
mutations) on the structural dynamics of NQO1, we sought a single metric that would respond, at least
semi-quantitatively, to the different types of change observed upon ligand binding (Figures 5 and 6).
We must note that these changes include a variety of effects on the amplitudes of the two kinetic phases
(sometimes increasing, decreasing, not changing or even shifting between the amplitudes of the burst
and the slow phases upon ligand binding) and also on the rate constant of the slow phase (in some
cases, this phase was too fast or slow to be measured adequately) (see Tables S1 and S2). Notably,
all these effects on the HDX kinetics can be simplified to a common effect: at least a few of the data
in the time-dependent measurements differ from two samples when these samples are paired for a
given time point (see Figure 6 for representative examples). Thus, we decided to simply calculate
the difference between the two paired proteins species for a given time and protein segment, and for
each segment, to average the three time points with a maximal difference in these time series. Indeed,
this simple metric (called ∆%Dav) was able to detect and rank the effects of ligand binding on NQO1
HDX due to changes in amplitudes and kinetic rate constants (Figure 6).
We compared again the behavior of NQO1holo vs. NQO1apo using ∆%Dav (Figure 7A and
Figure S10A). The results showed that FAD binding substantially reduced the backbone dynamics of
residues 11–20 (loop L1 and helix α1), 46–76 (loops L2 and L3, helix α7 and sheet β6), 103–113 (sheet β6
and loop L4), 149–165 (loop L6) and 191–211 (loop L7 and helix α5) (Figure 7A). These regions include
most of the residues involved in the MMI and FBS, and also some belonging to the DBS (Figure 7A,B).
When we evaluated the effect of dicoumarol binding, we observed further structural stabilization of all
these regions (with the exception of residues 191–211) and a specific stabilization of two additional
regions mostly involved in the MMI and DBS: a dramatic stabilization of the segment 120–141 (loop 5)
and a moderate effect in the segment 223–240 (loops L8 and L9 and sheets β8 and β9).
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(∆%Dav). (A) ∆%Dav for NQO1 segments upon binding FAD (NQO1holo) and dicoumarol (NQO1dic),
using NQO1apo as a reference. Residues belonging to the MMI, FBS and DBS are indicated (retrieved
as in Figure 2). (B) Representation of ∆%Dav onto the structure of NQO1 (using PDB 2F1O). The upper
row shows results for the ∆%Dav of NQO1holo and the lower row represents NQO1dic. Different panels
in each row show results for residues involved in the FBS, DBS or MMI.
3.4. Insights into Cooperative Effects upon FAD and Dicoumarol Binding from Analysis of Structural
Dynamics
In addition to the overall conformational and functional consequences of FAD and dicoumarol
binding to NQO1, some experimental techniques have revealed complexity in the functional chemistry
of this enzyme [22,23,41]. This behavior is not unexpected since binding of FAD to NQO1apo
and dicoumarol to NQO1holo is described by a general formalism for binding of a ligand (L) to a
macromolecule (P, NQO1 dimer) with two binding sites (Scheme 2) [42]:Biomolecules 2019, 9, x FOR PEER REVIEW 13 of 17 
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in which K1 and K2 describe the step-wise equilibrium constants as follows:
K1 =
[PL]
[P]·[L]
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K2 =
[PL2]
[PL]·[L]
For a P with two equivalent and non-interacting binding sites, these two step-wise equilibrium
binding constants are related through a simple relationship: K1 = 4·K2. Significant deviations from this
relationship imply the existence of non-equivalent or interacting sites: K1 > 4·K2 implies either negative
cooperativity or non-equivalent binding sites, while K1 < 4·K2 unequivocally identifies positive
cooperativity. It must be noted that, in this scenario, the largest differences between cooperative and
non-cooperative binding are found for the dependence of the population of the half-ligated species
[PL] (e.g., NQO1 dimer with one FAD bound) on [L] [22,23,42].
The NQO1 dimer contains two binding sites for either FAD or dicoumarol. Interestingly,
calorimetric titrations of NQO1apo with FAD and NQO1holo with dicoumarol, as well as inhibition
studies in the case of dicoumarol, have identified the existence of negative cooperativity in the binding
of both ligands [22,23,41]. A detailed structural characterization of the communication between ligand
binding sites underlying these cooperative effects is challenging for several reasons. First, in the ligand
binding equilibrium, the unligated (P), half-ligated (PL) and fully-ligated (PL2) species contribute
structurally and energetically to the observed cooperative binding. However, to date, no structural
information on the P or PL states for FAD binding is available (i.e., no high-resolution structure
of NQO1apo or the intermediate species with a single FAD molecule bound per dimer), while for
dicoumarol binding, no structural information for PL (NQO1holo with a single dicoumarol molecule
bound per dimer) is available. Although our current HDXMS study does not report on half-ligated
species, we were able to identify a network of interacting residues in NQO1apo that connect structurally
and energetically the FBS and the DBS between monomers through the MMI interface. Therefore,
our results suggest the existence of a highly dynamic structural network connecting these binding
sites between the monomers in NQO1, and these results may also provide a blueprint for future
experimental and computational mutagenesis studies aimed at perturbing and analyzing the role of this
network in ligand binding energetics and cooperativity. In support of this hypothesis, recent work has
shown that the mutation Gly151Ser (Gly150 according to the crystal structure) essentially prevents the
communication of ligand binding effects between the two DBS across the NQO1 dimer [41]. Gly151 is
located in the beginning of loop L6, and it undergoes a noticeable decrease in structural dynamics
upon dicoumarol binding (Figure 7), which might constitute part of the allosteric signal generated by
dicoumarol binding to one site (to form the half-ligated state PL), which communicates to the other
subunit contributing to the negative cooperativity for dicoumarol binding. More globally, our analyses
from HDXMS support the idea that dicoumarol binding triggers changes in NQO1 dynamics for certain
(but not all) regions predicted by studies using a Gaussian network approach on structural models for
the P and PL states [41]. In agreement with this recent study, we observed that dicoumarol binding
affected the dynamics of loops L3 and L5, sheets β6 and β7, and helices α2, α5 and α7, which showed
the largest changes in dynamics when the slowest frequency modes were analyzed upon formation of
the PL state by a Gaussian network model (Figure 7 vs. [41]).
4. Conclusions
The multifunctional nature of NQO1 is likely controlled, to a large extent, by changes in protein
structural dynamics triggered by the binding of small molecules (FAD, NAD(P)H, substrates, inhibitors)
as well as by interaction with other biomacromolecules (proteins and nucleic acids). These structural
and energetic aspects are critical to improve our understanding of these interactions under physiological
and pathological conditions. In this work, we showed that the use of HDXMS can be instrumental to
provide unprecedented detail of the effects of ligand binding on the functional chemistry of NQO1
linked to changes in protein structural dynamics. This approach may provide novel insights into
the regulation of NQO1 activity and stability in vivo, as well as the mechanisms by which these
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properties are regulated and/or dysregulated by disease-associated single amino acid exchanges and
post-translational modifications.
NQO1 is one of the human flavoproteins for which intracellular protein levels are more strongly
coupled to the intracellular availability of the flavin cofactor [25]. Our current understanding of
this phenomenon proposes that this sensitivity of protein stability is due to efficient recognition and
degradation of human apo-flavoproteins by the ubiquitin-dependent proteasomal pathway [14,25,30].
The lack of high-resolution information on the structure and dynamics of human apo-flavoproteins,
due to the instability of these apo-proteins, has prevented us from a deep understanding of these
recognition mechanisms. The detailed analysis reported herein for NQO1apo supports that HDXMS
can also be used to improve our understanding of this phenomenon as well as the mechanisms
by which disease-associated mutations and post-translational modifications may alter protein
structural dynamics, leading to alternative recognition mechanisms by the proteasomal degradation
pathway [14,30,34,36].
In this work, we identified a minimally stable core that allows NQO1apo to exist as a dimer, although
this dimer constitutes a highly dynamic conformational ensemble and with marginal conformational
stability. This core may serve as a wiring network that allows the communication of ligand binding
and mutational effects between domains and between subunits through this minimally stable MMI
(see [9,22,23,32,33]), and cooperative effects upon FAD and dicoumarol binding [22,23,41].
Our study also allows us to discuss the deleterious effects of the common cancer-associated
polymorphism Pro187Ser. Pro187 belongs to sheet β5, as a part of the stable core of the monomer in
NQO1apo state (Figure 3). Thus, the strong structural perturbation presumably caused by Pro187Ser
substitution could readily cause long-range effects on the structural dynamics of NQO1apo by disrupting
this stable core, and these effects could propagate within the monomer and between subunits in
the dimer. This interpretation agrees with previous experimental, computational and structural
perturbation analyses carried out on the Pro187Ser variant [5,14,22,30–34,36]. Consequently, even in
NQO1apo, the cancer-associated polymorphism Pro187Ser would destabilize the NQO1 monomer,
and this effect could easily propagate to the MMI, the FBS and the DBS, thus contributing to explain
the low conformational stability of P187S in vitro, its low affinity for FAD and dicoumarol, and its
accelerated degradation by the proteasome [9,10,14,22–25,34].
Our analyses also support that HDXMS can provide unprecedented structural insight into the
catalytic cycle of NQO1. First, our results indicate that FAD binding shifts the conformational ensemble
of NQO1 towards more stable and competent states for either NAD(P)H or dicoumarol binding (i.e.,
at the DBS). This effect is further strengthened upon the binding of the inhibitor, suggesting that the
structural dynamics of the DBS (and plausibly of the NAD(P)H binding site; [15]) acts by limiting the
available ligand binding poses of NAD(P)H. This would optimize hydride transfer from the adenine
dinucleotide coenzyme to the FAD, thus contributing to high rate constants experimentally measured
for the reductive half-reaction catalyzed by NQO1 [10].
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